Royal Bank of Canada
INDP icon

Royal Bank of Canada’s Indaptus Therapeutics INDP Stock Holding History

Royal Bank of Canada’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed – – 7267
2023
Q4 		$0 Buy
+1
New +$63 ﹤0.01% 7330
2020
Q2 		– Hold
0
– – – 6743
2020
Q1 		– Hold
0
– – – 6829
2019
Q4 		– Hold
0
– – – 6658
2019
Q3 		– Hold
0
– – – 6455
2019
Q2 		– Hold
0
– – – 6389

Other funds holding INDP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.53B AUM 36.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada's INDP Position: Q1 2024 in Review

Royal Bank of Canada sold out of Indaptus Therapeutics (INDP) in Q1 2024, closing a stake of 1 share.

Royal Bank of Canada first reported a position in INDP in Q4 2023 and held it in 1 quarter. The position peaked at $0 in Q4 2023. 15 funds tracked by Wall St. Rank hold INDP as of Q1 2024.

  • Royal Bank of Canada reported no remaining Indaptus Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 1 Indaptus Therapeutics share in Q1 2024.
  • Royal Bank of Canada first reported a position in Indaptus Therapeutics in Q4 2023 and held it in 1 quarter.
  • Royal Bank of Canada's Indaptus Therapeutics position peaked at $0 in Q4 2023.
  • 15 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2024.

Based on Royal Bank of Canada's 13F filing for Q1 2024, filed 15 May 2024.